Multiple epidermotropic melanoma metastases developing during **BRAF** and **MEK** inhibitor therapy

Raphael Reinhard, MD,a,b Christoffer Gebhardt, MD,a,b Nolwenn Maurier, MD,a Lionel Larribère, PhD,a,b Azadeh Orouji, MD,a and Jochen Utikal, MD,a,b

**Mannheim and Heidelberg, Germany**

**Key words:** **BRAF**, **MEK**, melanoma; metastases; targeted therapy.

**INTRODUCTION**

Since introduction of **BRAF** and **MEK** inhibition therapy, there has been a significant improvement in response rates, overall survival, and progression-free disease in melanoma patients. Combined **BRAF** and **MEK** inhibition, compared with **BRAF** inhibition alone, has shown to delay the emergence of resistance in patients suffering from **BRAF** V600E–mutated advanced melanoma. It has become the standard of care in patients carrying this mutation. Several mechanisms of resistance to **BRAF** and **MEK** inhibition have been shown. Reactivation of the mitogen-activated protein kinase pathway is the major trigger in more than two-thirds of tumors.

**CASE REPORT**

We report on a 63-year-old patient who had solely multiple eruptive verrucous epidermotropic melanoma metastases of the lower limb during **BRAF** and **MEK** inhibitor therapy with dabrafenib and trametinib. To our knowledge, this is the first description of a solely cutaneous progressive disease during **BRAF** and **MEK** therapy.

The patient had a primary nonulcerated melanoma of the left foot diagnosed in 2012. The Breslow tumor thickness was 2.5 mm. After the sentinel lymph node was diagnosed positive in the left groin, the patient underwent radical lymphadenectomy (2 of 12 lymph nodes positive). A mutational analysis revealed a **BRAF** V600E mutation. One year later, the patient presented to our ward with multiple liver and bone metastases. Because of the **BRAF** V600E mutation, the patient was treated with dabrafenib and trametinib. The medication was tolerated well and without any adverse effects. Radiology images showed partial response over 14 months. The patient was closely monitored with computed tomography scans of the body and cerebral magnetic resonance imaging every 2 to 3 months using RECIST 1.1 criteria. Suddenly after 14 months of treatment with dabrafenib and trametinib, the patient developed multiple verrucous epidermotropic nodules of the left limb and lower abdomen in May 2014 as presented in Fig 1, A. The bone and liver metastases remained stable. Most lesions presented with a white halo around the dark central nodule. Histologically, the lesions presented as epidermotropic, pleomorphic melanoma metastases, as shown in Fig 2. Solar elastosis was also present, highly suggesting previous sun damage to the skin. Four large cutaneous metastases were excised. Others were treated with CO2 laser
therapy and topical imiquimod (Fig 1, B) showing complete resolutions after an initial inflammation owing to imiquimod treatment. The disease remained stable for another 7 months until February 2015, when the patient experienced a relapse with multiple para-aortal, paraaortic, inguinal, and brain metastases. The treatment was switched to radiation therapy (brain and lymph node metastases) and ipilimumab. Because of progressive disease, the treatment was switched to pembrolizumab 3 months later. The patient deceased another 3 months later.

CONCLUSION
We present a rare case of multiple eruptive verrucous epidermotropic melanoma metastases during treatment with BRAF and MEK inhibitors. Visceral metastases regressed or remained stable during this therapy. This finding could be because of the reactivation of the mitogen-activated protein kinase pathway known as the major trigger of resistance, solely in an epidermotropic melanoma cell subclone of our patient. Cutaneous metastases of malignant melanoma often represent the first sign of relapse of this fatal disease. Clinically and histologically cutaneous metastases present in various forms. Most commonly, cutaneous metastasis is primarily composed of epithelioid cells. However, epidermotropic metastases as seen in our case are rare.

Our case shows that CO2 laser therapy and adjuvant imiquimod therapy can be successfully applied to control the local appearance of epidermotropic melanoma metastases.
REFERENCES

1. Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248-1260.

2. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451.

3. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877-1888.

4. Stadler S, Weina K, Gebhardt C, Utikal J. New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci. 2015;60(1):83-88.

5. Roesch A, Paschen A, Landsberg J, Helfrich I, Becker JC, Schadendorf D. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. Eur J Cancer. 2016;59:109-112.

6. Tas F, Erturk K. Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors. Melanoma Res. 2017;27(2):134-139.

7. Plaza JA, Torres-Cabala C, Evans H, Diwan HA, Suster S, Prieto VG. Cutaneous metastases of malignant melanoma: a clinicopathologic study of 192 cases with emphasis on the morphologic spectrum. Am J Dermatopathol. 2010;32(2):129-136.

8. Utikal J, Zimpfer A, Thoelke A, et al. Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod. Br J Dermatol. 2006;155(2):488-491.

9. Van Jarwaarde JA, Wessels R, Nieweg OE, Wouters MW, van der Hage JA. CO2 laser treatment for regional cutaneous malignant melanoma metastases. Dermatol Surg. 2015;41(1):78-82.

Fig 2. Histology of epidermotropic melanoma metastases. (A, Hematoxylin-eosin stain; B, anti-S100B stain.)